Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterised by progressive motor function decline. Motor function is assessed using several functional outcome measures including the Revised Hammersmith Scale (RHS).

Objective: In this study, we present longitudinal trajectories for the RHS in an international cohort of 149 untreated paediatric SMA 2 and 3 patients (across 531 assessments collected between March 2015 and July 2019).

Methods: We contextualise these trajectories using both the Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM). At baseline, this cohort included 50% females and 15% of patients had undergone spinal fusion surgery. Patient trajectories were modelled using a natural cubic spline with age, sex, and random effects for each patient.

Results: RHS and HFMSE scores show similar trends over time in this cohort not receiving disease modifying therapies. The results confirm the strong correlation between the RHS and RULM previously observed in SMA types 2 and 3a. Scoliosis surgery is associated with a reduction of 3 points in the RHS, 4.5 points in the HFMSE for the SMA 2 population, and a reduction of 11.8 points in the RHS, and 13.4 points in the HFMSE for the SMA 3a populations. When comparing the RHS and RULM, there is a lower correlation in the type 3a's than the type 2 patients. In the SMA 2 population, there is no significant difference between the sexes in either the RHS or HFMSE trajectories. There is no significant difference in the RULM trajectory in the SMA 2 or 3a participants by sex.

Conclusions: This study demonstrates that the RHS could be used in conjunction with other functional measures such as the RULM to holistically detect SMA disease progression. This will assist with fully understanding changes that occur with treatments, further defining trajectories and therapy outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091622PMC
http://dx.doi.org/10.3233/JND-230211DOI Listing

Publication Analysis

Top Keywords

revised hammersmith
8
hammersmith scale
8
spinal muscular
8
muscular atrophy
8
sma
8
motor function
8
rhs
8
rhs hfmse
8
rhs rulm
8
points rhs
8

Similar Publications

Spinal muscular atrophy (SMA) types 2 and 3 are chronic neuromuscular disorders characterized by progressive motor impairment. Although disease-modifying therapies such as risdiplam and nusinersen have shown clinical efficacy, real-world data in pediatric populations remain limited. This prospective observational study evaluated motor function outcomes in 20 children with SMA (aged 3 to 13 years; 12 with type 2, 8 with type 3) receiving either risdiplam or nusinersen in Northwestern Iran.

View Article and Find Full Text PDF

Background And Objectives: The clinical spectrum of spinal muscular atrophy (SMA) is heterogenous and depends on several factors. This study aimed to investigate the correlation between the motor outcomes and genetic modifiers of SMN1 gene.

Methods: In this cross-sectional study, children with genetically confirmed diagnosis of SMA were enrolled.

View Article and Find Full Text PDF

Background: The clinical use of three disease-modifying drugs approved in Japan for the treatment of spinal muscle atrophy (SMA) has increased. Therefore, there is an increasing need for biomarkers to evaluate therapeutic interventions.

Methods: Individuals were treated with risdiplam (25 patients, male:female =12:13) and evaluated before starting the medication and after 1, 2, 5, 8, and 12 months.

View Article and Find Full Text PDF

Longitudinal efficacy of risdiplam treatment in Chinese children with spinal muscular atrophy.

Orphanet J Rare Dis

July 2025

Department of Neurology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, 310052, China.

Background: As the latest drug available for the treatment of spinal muscular atrophy (SMA), real-world research data on risdiplam are still lacking. The purpose of this study was to supplement the real-world data in SMA children receiving risdiplam by studying children in multiple centers throughout China.

Results: In total, 34 children with SMA were collected from September 2021 to November 2024 and followed for a period of 8.

View Article and Find Full Text PDF

The role of SLC19A2 variants in the wide spectrum of non-autoimmune abnormalities of glucose homeostasis.

Diabetologia

July 2025

Research Unit of Diabetes and Endocrine Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.

Aims/hypothesis: Biallelic pathogenic variants in SLC19A2 (the solute carrier family 19 member 2, which encodes thiamine transporter 1, responsible for thiamine intake) cause a recessive syndromic diabetes of infancy or early childhood in the context of thiamine-responsive megaloblastic anaemia, characterised by sensorineural deafness. Indeed, it has been reported, although only once, that even a heterozygous missense loss-of-function variant of SLC19A2 causes dominantly inherited non-syndromic diabetes. Finally, it is unknown whether rare SLC19A2 pathogenic variants modulate the risk of type 2 diabetes at the population level.

View Article and Find Full Text PDF